Journal
ATHEROSCLEROSIS
Volume 205, Issue 2, Pages 561-567Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2008.12.028
Keywords
Ischemic stroke classification; Cardioembolic stroke; Atherothrombotic stroke; Proteomics
Funding
- Spanish Ministry of Health (Instituto de Salud Carlos III) [RETICS-RD06/0026]
- Xunta de Galicia (Conselleria de Sanidade) [Codigo PS07/29]
- Conselleria de Educacion e Ordenacion Universitaria of Xunta de Galicia
- Axudas para a Consolidacion e Estruturacion de Uniclades de lnvestigacion Competitivas [80/2006]
- Fundacion de investigacion Medica Mutua Madrilena
Ask authors/readers for more resources
Objective: To identify protein biomarkers in order to classify ischemic stroke subtypes using proteomic analysis and immunoenzymatic tools for clinical validation. Methods and results: We performed a proteomic analysis in serum samples of 24 patients with ischemic stroke (12 atherothrombotic patients and 12 cardioembolic patients). In this study, based on two-dimensional electrophoresis and mass spectrometry we found four spots whose expression intensity was at least four times stronger in atherothrombotic patients than in cardioembolic patients. These spots were identified as haptoglobin related protein, serum amyloid A (two spots) and haptoglobin alpha chain. We validated the possible value of haptoglobin and serum amyloid A in a larger series of patients (n = 262) with ischemic stroke using ELISA techniques. Haptoglobin levels > 1040 mu g/mL identified atherothrombotic patients with 95% sensitivity and 88% specificity whereas serum amyloid A levels > 160 mu g/mL identified atherothrombotic patients with 91% sensitivity and 83% specificity. Conclusions: Haptoglobin and serum amyloid A are useful biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available